| Literature DB >> 26452384 |
Amine Belaid, Papa Diogop Ndiaye, Harilaos Filippakis, Jérémie Roux, Éric Röttinger, Yacine Graba, Patrick Brest, Paul Hofman, Baharia Mograbi1.
Abstract
Survival rates of patients with metastatic or recurrent cancers have remained virtually unchanged during the past 30 years. This fact makes the need for new therapeutic options even more urgent. An attractive option would be to target autophagy, an essential quality control process that degrades toxic aggregates, damaged organelles, and signaling proteins, and acts as a tumor suppressor pathway of tumor initiation. Conversely, other fascinating observations suggest that autophagy supports cancer progression, relapse, metastasis, dormancy and resistance to therapy. This review provides an overview of the contradictory roles that autophagy plays in cancer initiation and progression and discusses the promises and challenges of current strategies that target autophagy for cancer therapy.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26452384 DOI: 10.2174/156800961508151001102452
Source DB: PubMed Journal: Curr Cancer Drug Targets ISSN: 1568-0096 Impact factor: 3.428